Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 16/20 | 0.41 |
| ▸ | TACR3 | P29371 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP5 | P51878 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5527526 | 0.88 | TACR1 (0.43) | GPBAR1TACR1CYP1A2CYP2C19 | |
| SCHEMBL5528780 | 0.87 | TACR1 (0.38) | GPBAR1TACR1TACR3CYP2D6MEN1 | |
| SCHEMBL6095509 | 0.86 | TACR1 (0.41) | GPBAR1TACR1CYP3A4 | |
| SCHEMBL5534458 | 0.86 | TACR1 (0.43) | GPBAR1TACR1CYP1A2CYP2C19CASP1 | |
| SCHEMBL6095621 | 0.86 | TACR1 (0.39) | TACR1CYP3A4CASP1CASP5 | |
| SCHEMBL6093917 | 0.84 | TACR1 (0.40) | TACR1CYP2D6CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6093692 | 0.83 | TACR1 (0.39) | TACR1CYP3A4 | |
| SCHEMBL6094847 | 0.83 | TACR1 (0.36) | GPBAR1TACR1CYP2D6CYP3A4 | |
| SCHEMBL5530963 | 0.83 | TACR1 (0.41) | GPBAR1TACR1 | |
| SCHEMBL5533230 | 0.83 | TACR1 (0.44) | GPBAR1TACR1CYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1489083-B1 | FUSED BICYCLIC PYRIDINE DERIVATIVE AS TACHYKININ RECEPTOR ANTAGONIST | KYORIN SEIYAKU KK (JP) | 2007-06-06 | — | — | EP | disclosed |
| US-7026309-B2 | Fused bicyclic pyridine derivative as tachykinin receptor antagonist | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2006-04-11 | — | — | US | disclosed |
| US-20050101591-A1 | Fused bicyclic pyridine derivative as tachykinin receptor antagonist | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1489083-A1 | FUSED BICYCLIC PYRIDINE DERIVATIVE AS TACHYKININ RECEPTOR ANTAGONIST | Kyorin Pharmaceutical Co., Ltd. (JP) | 2004-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101591-A1 | Fused bicyclic pyridine derivative as tachykinin receptor antagonist | BDKRB1, BDKRB2, NPY1R | GPBAR1 179/4885TACR1 4/4885TACR3 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.